Quest PharmaTech Inc. announced that it has achieved 50% accrual having enrolled the 40(th) patient in its ongoing 80 patient Phase II Oregovomab front-line chemo-immunotherapy clinical trial in Italy and the U.S. The objective of this study is to confirm that optimally dosed oregovomab in combination with standard front-line chemotherapy for advanced ovarian cancer will generate an improved immune and clinical response, as seen in preliminary phase II studies, and permit the best design of a definitive phase III program to follow. Currently, there are 8 clinical trial centers in Italy enrolling patients, with Professor Roberto Angioli at Policlinico Universitario Campus Bio-Medico Di Roma acting as the study chair. The Company is adding three additional centers in the U.S., to the two active U.S. sites, through the COGI clinical trials group, under the leadership of Professor Jonathan Berek at the Stanford Women's Cancer Center, Stanford Cancer Institute.